{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}],"title":"Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Grade 3-4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"}],"units":"Participants"}],"description":"Tacrolimus and Methotrexate used for acute graft versus host disease (aGVHD) prophylaxis, clinical grading AGVHD criteria (Days 1-100): Grade 1: + to ++ skin rash; no gut involvement; no decrease in clinical performance status; Grade 2: + to +++ skin rash; + gut involvement and/or + liver involvement; mild decrease in performance status; Grade 3: ++ to +++ skin rash; ++ to +++ gut involvement and/or ++ to ++++ liver involvement; marked decrease in performance status; Grade 4: Similar to Grade 3 with ++ to ++++ organ involvement and extreme decrease in performance status.","groups":[{"description":"Busulfan starting 0.8 mg/kg by vein (IV) every 6 hours for 12 doses; Fludarabine 30 mg/m\\^2 IV daily for 4 days.","id":"OG000","title":"Tacrolimus + Methotrexate"}],"paramType":"NUMBER","populationDescription":"Analysis was per protocol for 73 patients out of 80 patients due to 3 early deaths and 4 non engraftments.","reportingStatus":"POSTED","timeFrame":"5 years","title":"Number of Participants With Graft Versus Host Disease (GVHD)","type":"SECONDARY","unitOfMeasure":"Participants"}